

Vicki L Ellingrod

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1576032/publications.pdf>

Version: 2024-02-01

107
papers

3,160
citations

172457

29
h-index

175258

52
g-index

109
all docs

109
docs citations

109
times ranked

4022
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacogenetics of Methadone for Pain Management in Palliative Care. <i>Journal of Pain and Symptom Management</i> , 2022, 63, e142-e145.	1.2	1
2	Psychiatrist and Psychiatric Pharmacists Beliefs and Preferences for Atypical Antipsychotic Treatments in Patients With Schizophrenia and Bipolar Disorders. <i>Journal of Pharmacy Practice</i> , 2021, 34, 78-88.	1.0	2
3	Use of psychiatric medication by college students: A decade of data. <i>Pharmacotherapy</i> , 2021, 41, 350-358.	2.6	11
4	Pharmacogenomic testing for mental health (Part I): documenting early adopter perceptions of use for eight scenarios. <i>Personalized Medicine</i> , 2021, 18, 223-232.	1.5	1
5	Genetic and Metabolite Variability in One-Carbon Metabolism Applied to an Insulin Resistance Model in Patients With Schizophrenia Receiving Atypical Antipsychotics. <i>Frontiers in Psychiatry</i> , 2021, 12, 623143.	2.6	2
6	Pharmacogenomic testing for mental health (Part II): qualitative analysis of early adopter prescriber perceptions. <i>Personalized Medicine</i> , 2021, 18, 233-240.	1.5	0
7	Sexual Functioning in Adolescents With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	2
8	Could Dietary Glutamate Play a Role in Psychiatric Distress?. <i>Neuropsychobiology</i> , 2020, 79, 13-19.	1.9	21
9	Establishment of a Pharmacogenetics Service Focused on Optimizing Existing Pharmacogenetic Testing at a Large Academic Health Center. <i>Journal of Personalized Medicine</i> , 2020, 10, 154.	2.5	12
10	Dietary Glutamic Acid, Obesity, and Depressive Symptoms in Patients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 620097.	2.6	12
11	Metabolic syndrome is negatively associated with cognition among endothelial nitric oxide synthase (eNOS)-786C carriers in schizophrenia-spectrum disorders. <i>Journal of Psychiatric Research</i> , 2019, 117, 142-147.	3.1	2
12	3143 DIAMOND: A Digital Platform for Workforce Development. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 67-67.	0.6	0
13	The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis. <i>Schizophrenia Bulletin</i> , 2019, 45, 1170-1183.	4.3	44
14	Assessments of Research Competencies for Clinical Investigators: A Systematic Review. <i>Evaluation and the Health Professions</i> , 2019, 44, 016327871989639.	1.9	6
15	Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with Bipolar Disorder or Schizophrenia. <i>Pharmacotherapy</i> , 2019, 39, 161-170.	2.6	81
16	Patient perspectives on medication self-management in rural Kenya: a cross-sectional survey. <i>International Journal for Quality in Health Care</i> , 2019, 31, 353-358.	1.8	5
17	Using Pharmacogenomic Testing in Primary Care: Protocol for a Pilot Randomized Controlled Study. <i>JMIR Research Protocols</i> , 2019, 8, e13848.	1.0	1
18	Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia. <i>Pharmacotherapy</i> , 2018, 38, 638-650.	2.6	11

#	ARTICLE	IF	CITATIONS
19	Eye gaze perception in bipolar disorder: Self-referential bias but intact perceptual sensitivity. <i>Bipolar Disorders</i> , 2018, 20, 60-69.	1.9	17
20	A Bayesian model comparison approach to test the specificity of visual integration impairment in schizophrenia or psychosis. <i>Psychiatry Research</i> , 2018, 265, 271-278.	3.3	8
21	The Influence of Metabolic Syndrome and Sex on the DNA Methylome in Schizophrenia. <i>International Journal of Genomics</i> , 2018, 2018, 1-12.	1.6	15
22	Competency indices to assess the knowledge, skills and abilities of clinical research professionals. <i>International Journal of Clinical Trials</i> , 2018, 5, 46.	0.2	15
23	Supplemental Use of Complementary Alternative Medicine for the Treatment of Schizophrenia. <i>Psychiatric Annals</i> , 2018, 48, 211-213.	0.1	0
24	Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia. <i>Pharmacotherapy</i> , 2017, 37, 1122-1130.	2.6	15
25	Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort. <i>Pharmacotherapy</i> , 2017, 37, 261-267.	2.6	207
26	Precision Pharmacotherapy Enables Precision Medicine. <i>Pharmacotherapy</i> , 2017, 37, 985-987.	2.6	5
27	Germline genetic variants with implications for disease risk and therapeutic outcomes. <i>Physiological Genomics</i> , 2017, 49, 567-581.	2.3	8
28	Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy. <i>Pharmacogenomics</i> , 2017, 18, .	1.3	2
29	Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers. <i>AAPS Journal</i> , 2017, 19, 1513-1522.	4.4	21
30	Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder. <i>Clinical Schizophrenia and Related Psychoses</i> , 2017, 11, 39-48.	1.4	25
31	Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders. <i>Psychopharmacology Bulletin</i> , 2017, 47, 8-21.	0.0	11
32	Gene-specific DNA methylation may mediate atypical antipsychotic-induced insulin resistance. <i>Bipolar Disorders</i> , 2016, 18, 423-432.	1.9	27
33	Oxytocin Receptor (OXTR) Methylation and Cognition in Psychotic Disorders. <i>Molecular Neuropsychiatry</i> , 2016, 2, 151-160.	2.9	15
34	Identification of non-reported bupropion metabolites in human plasma. <i>Biopharmaceutics and Drug Disposition</i> , 2016, 37, 550-560.	1.9	10
35	Negative affect predicts social functioning across schizophrenia and bipolar disorder: Findings from an integrated data analysis. <i>Psychiatry Research</i> , 2016, 243, 198-206.	3.3	26
36	Interaction between COMT rs5993883 and second generation antipsychotics is linked to decreases in verbal cognition and cognitive control in bipolar disorder. <i>BMC Psychology</i> , 2016, 4, 14.	2.1	13

#	ARTICLE	IF	CITATIONS
37	An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar Disorder. <i>Clinical and Translational Science</i> , 2015, 8, 432-440.	3.1	25
38	The effect of folate supplementation and genotype on cardiovascular and epigenetic measures in schizophrenia subjects. <i>NPI Schizophrenia</i> , 2015, 1, 15046.	3.6	16
39	The Microbiome in Mental Health: Potential Contribution of Gut Microbiota in Disease and Pharmacotherapy Management. <i>Pharmacotherapy</i> , 2015, 35, 910-916.	2.6	42
40	The development of depressive symptoms during medical internship stress predicts worsening vascular function. <i>Journal of Psychosomatic Research</i> , 2015, 79, 243-245.	2.6	11
41	DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder. <i>Epigenomics</i> , 2015, 7, 343-352.	2.1	29
42	Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders. <i>Schizophrenia Research</i> , 2015, 164, 115-121.	2.0	13
43	Team-Based Learning to Improve Learning Outcomes in a Therapeutics Course Sequence. <i>American Journal of Pharmaceutical Education</i> , 2014, 78, 13.	2.1	41
44	Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics. <i>Pharmacogenomics</i> , 2014, 15, 61-67.	1.3	12
45	Effects of Cigarette Smoking on Metabolism and Effectiveness of Systemic Therapy for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 917-926.	1.1	99
46	Vitamin D Receptor Genetics on Extracellular Matrix Biomarkers and Hemodynamics in Systolic Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 439-445.	2.0	13
47	Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. <i>Bipolar Disorders</i> , 2014, 16, 277-288.	1.9	77
48	Detection of Metabolic Syndrome in Schizophrenia and Implications for Antipsychotic Therapy. <i>Molecular Diagnosis and Therapy</i> , 2013, 17, 21-30.	3.8	25
49	P-glycoprotein (PGP) Polymorphisms and Sexual Dysfunction in Female Patients With Depression and SSRI-Associated Sexual Side Effects. <i>Journal of Sex and Marital Therapy</i> , 2013, 39, 280-288.	1.5	19
50	Fatty Acid Desaturase Gene Polymorphisms and Metabolic Measures in Schizophrenia and Bipolar Patients Taking Antipsychotics. <i>Cardiovascular Psychiatry and Neurology</i> , 2013, 2013, 1-8.	0.8	16
51	A Pilot Study Investigating Tumor Necrosis Factor- α as a Potential Intervening Variable of Atypical Antipsychotic-Associated Metabolic Syndrome in Bipolar Disorder. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 194-202.	2.0	11
52	Genetic Variations in TGF β 1, tPA, and ACE and Radiation-Induced Thoracic Toxicities in Patients with Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 208-213.	1.1	19
53	759C/T Variants of the Serotonin (5-HT _{2C}) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment. <i>Clinical Pharmacology & Biopharmaceutics</i> , 2013, 02, 110.	0.2	12
54	Atypical antipsychotics attenuate associations between linoleic acid and reduced markers of metabolic syndrome. <i>FASEB Journal</i> , 2013, 27, 1067.5.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Risk Factors Associated With Metabolic Syndrome in Bipolar and Schizophrenia Subjects Treated With Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 261-265.	1.4	76
56	Cryptochrome 2 variants, chronicity, and seasonality of mood disorders. <i>Psychiatric Genetics</i> , 2012, 22, 305-306.	1.1	12
57	DNA methylation in schizophrenia subjects: gender and <i>MTHFR</i> 677C/T genotype differences. <i>Epigenomics</i> , 2012, 4, 261-268.	2.1	45
58	Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. <i>Current Psychiatry Reviews</i> , 2012, 8, 25-36.	0.9	63
59	Association of plasma omega-3 and omega-6 lipids with burden of disease measures in bipolar subjects. <i>Journal of Psychiatric Research</i> , 2012, 46, 1435-1441.	3.1	25
60	Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction. <i>Psychiatry Research</i> , 2012, 199, 74-76.	3.3	16
61	Fats and Factors: Lipid Profiles Associate with Personality Factors and Suicidal History in Bipolar Subjects. <i>PLoS ONE</i> , 2012, 7, e29297.	2.5	31
62	Schizophrenia and folate pharmacogenetics: Review of the literature regarding folic acid and its pharmacogenetically regulated metabolism in relation to schizophrenia treatments. <i>Mental Health Clinician</i> , 2012, 1, 225-229.	1.0	1
63	Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs). <i>Schizophrenia Research</i> , 2011, 130, 20-26.	2.0	34
64	Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. <i>Psychiatry Research</i> , 2011, 187, 74-79.	3.3	19
65	Factors Associated with the Prescribing of Olanzapine, Quetiapine, and Risperidone in Patients with Bipolar and Related Affective Disorders. <i>Pharmacotherapy</i> , 2011, 31, 806-812.	2.6	12
66	Association between type 3 metabotropic glutamate receptor gene (<i>GRM3</i>) variants and symptom presentation in treatment refractory schizophrenia. <i>Human Psychopharmacology</i> , 2011, 26, 28-34.	1.5	24
67	Anxiety, Depression, and Cognitive Impairment in Dementia-Specific and Traditional Assisted Living. <i>Journal of Gerontological Nursing</i> , 2010, 36, 18-30.	0.6	14
68	A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (<i>ADRB1</i>) on cardiac vital signs in depressed patients: a novel pharmacogenetic approach. <i>Psychopharmacology Bulletin</i> , 2010, 43, 11-22.	0.0	6
69	Introduction to the College of Psychiatric and Neurologic Pharmacists 2009 Poster Abstracts. <i>Journal of Pharmacy Practice</i> , 2009, 22, 202-202.	1.0	0
70	The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. <i>Human Psychopharmacology</i> , 2009, 24, 207-215.	1.5	49
71	Leptin Gene "2548G/A variants predict risperidone-associated weight gain in children and adolescents. <i>Psychiatric Genetics</i> , 2009, 19, 320-327.	1.1	47
72	Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (<i>MTHFR</i>) 677C/T and 1298A/C variants. <i>Schizophrenia Research</i> , 2008, 98, 47-54.	2.0	93

#	ARTICLE	IF	CITATIONS
73	Tales from the field: what the nursing research textbooks will not tell you. <i>Applied Nursing Research</i> , 2008, 21, 232-236.	2.2	3
74	Dementia-Specific Assisted Living: Clinical Factors and Psychotropic Medication Use. <i>Journal of the American Psychiatric Nurses Association</i> , 2008, 14, 39-49.	1.0	10
75	Dementia Care in Assisted Living: Needs and Challenges. <i>Issues in Mental Health Nursing</i> , 2008, 29, 817-838.	1.2	14
76	Metabotropic Glutamate Receptor Genes as Candidates for Pharmacogenetic Studies of Current and Future Antipsychotic Agents in Schizophrenia. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2007, 5, 21-30.	0.3	2
77	Introduction To Pharmacogenomics. <i>Journal of Pharmacy Practice</i> , 2007, 20, 203-205.	1.0	2
78	Incorporating Pharmacogenomics into Practice. <i>Journal of Pharmacy Practice</i> , 2007, 20, 277-282.	1.0	10
79	Pharmacogenomics in Psychiatry. <i>Journal of Pharmacy Practice</i> , 2007, 20, 252-264.	1.0	2
80	LA allelic heterozygosity of the 5HTTLPR polymorphism is associated with higher cognitive function and lower interpersonal sensitivity. <i>Psychiatric Genetics</i> , 2007, 17, 3-4.	1.1	16
81	Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. <i>Psychiatric Genetics</i> , 2007, 17, 358.	1.1	17
82	Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. <i>Psychopharmacology Bulletin</i> , 2007, 40, 57-62.	0.0	62
83	The Relationship Between P-Glycoprotein (PGP) Polymorphisms and Response to Olanzapine Treatment in Schizophrenia. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 668-672.	2.0	51
84	Serotonin 2A α 1438 G/A and G-Protein Beta3 Subunit C825T Polymorphisms in Patients with Depression and SSRI-Associated Sexual Side-Effects. <i>Neuropsychopharmacology</i> , 2006, 31, 2281-2288.	5.4	90
85	The Association of Weight Gain and Olanzapine Plasma Concentrations. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 250-254.	1.4	45
86	Phobic anxiety in late-life in relationship to cognition and 5HTTLPR polymorphism. <i>Psychiatric Genetics</i> , 2005, 15, 305-306.	1.1	18
87	Weight gain associated with the α 759C/T polymorphism of the 5HT2C receptor and olanzapine. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2005, 134B, 76-78.	1.7	133
88	Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. <i>Schizophrenia Research</i> , 2005, 77, 253-260.	2.0	78
89	Pooled Analysis of Antidepressant Levels in Lactating Mothers, Breast Milk, and Nursing Infants. <i>American Journal of Psychiatry</i> , 2004, 161, 1066-1078.	7.2	274
90	Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response. <i>Pharmacogenomics</i> , 2004, 5, 463-477.	1.3	10

#	ARTICLE	IF	CITATIONS
91	Distribution of the serotonin 2C (5HT2C) receptor gene $\hat{\sim}$ 759C/T polymorphism in patients with schizophrenia and normal controls. <i>Psychiatric Genetics</i> , 2004, 14, 93-95.	1.1	8
92	CYP3A5 Polymorphism and the Ethnic Differences in Cyclosporine Pharmacokinetics in Healthy Subjects 1. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 524-528.	2.0	67
93	Association of the CYP3A4*1B 5 $\hat{\sim}$ -Flanking Region Polymorphism With Cyclosporine Pharmacokinetics in Healthy Subjects. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 305-309.	2.0	53
94	The Influence of Cognitive Impairment and Behavioral Dysregulation on Daily Functioning in the Nursing Home Setting. <i>American Journal of Psychiatry</i> , 2003, 160, 582-584.	7.2	20
95	5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia. <i>Psychopharmacology Bulletin</i> , 2003, 37, 109-12.	0.0	28
96	CYP2D6 polymorphisms and atypical antipsychotic weight gain. <i>Psychiatric Genetics</i> , 2002, 12, 55-58.	1.1	65
97	C3435T Mutation in Exon 26 of the Human MDR1 Gene and Cyclosporine Pharmacokinetics in Healthy Subjects. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 400-404.	2.0	84
98	Comparison of Risperidone with Olanzapine in Elderly Patients with Dementia and Psychosis. <i>Pharmacotherapy</i> , 2002, 22, 1-5.	2.6	32
99	Abnormal Movements and Tardive Dyskinesia in Smokers and Nonsmokers with Schizophrenia Genotyped for Cytochrome P450 2D6. <i>Pharmacotherapy</i> , 2002, 22, 1416-1419.	2.6	28
100	5HT2A and 5HT2C Receptor Polymorphisms And Predicting Clinical Response to Olanzapine in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 622-624.	1.4	36
101	The Influence of Cognitive Impairment and Psychiatric Symptoms on Daily Functioning in Nursing Facilities: A Longitudinal Study. <i>Annals of Clinical Psychiatry</i> , 2002, 14, 209-213.	0.6	13
102	Caregiver Report of Hallucinations and Paranoid Delusions in Elders Aged 70 or Older. <i>International Psychogeriatrics</i> , 2001, 13, 241-249.	1.0	20
103	Lack of menstrual cycle effects on hypothalamic- pituitary-adrenal axis response to insulin-induced hypoglycaemia. <i>Clinical Endocrinology</i> , 2000, 52, 781-787.	2.4	9
104	Pharmacogenetic Screening for Susceptibility to Fetal Malformations in Women. <i>Annals of Pharmacotherapy</i> , 2000, 34, 639-645.	1.9	16
105	Psychosexual effects of three doses of testosterone cycling in normal men. <i>Biological Psychiatry</i> , 1999, 45, 254-260.	1.3	122
106	The Effects of Anabolic Steroids on Driving Performance as Assessed by the Iowa Driver Simulator. <i>American Journal of Drug and Alcohol Abuse</i> , 1997, 23, 623-636.	2.1	18
107	Venlafaxine: A heterocyclic antidepressant. <i>American Journal of Health-System Pharmacy</i> , 1994, 51, 3033-3046.	1.0	3